menu
    • menu
    [{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ozenoxacin","moa":"DNA gyrase | DNA topoisomerase IV | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ozenoxacin","moa":"DNA gyrase | DNA topoisomerase IV | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Pelthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Licensing Agreement","leadProduct":"Ozenoxacin","moa":"DNA gyrase | DNA topoisomerase IV | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Biofrontera \/ Pelthos Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Pelthos Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Ozenoxacin

    Menu

    Ozenoxacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biofrontera

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Biofrontera

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ozenoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Pelthos Therapeutics

                            Deal Size : $10.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biofrontera Inc. Sells Xepi Antibiotic Cream License to Pelthos Therapeutics for $10M

                            Details : Through the licensing deal for Ozenoxacin, targeting DNA gyrase, DNA topoisomerase IV, and Topoisomerase IV, the agreement aims to advance treatment for impetigo.

                            Product Name : Xepi

                            Product Type : Antibiotic

                            Upfront Cash : $3.0 million

                            November 07, 2025

                            Lead Product(s) : Ozenoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Pelthos Therapeutics

                            Deal Size : $10.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ferrer Internacional

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ozenoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

                            Details : Ozenoxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Impetigo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2014

                            Lead Product(s) : Ozenoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ferrer Internacional

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            Ferrer Internacional

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ozenoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

                            Details : Ozenoxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Impetigo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2011

                            Lead Product(s) : Ozenoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth